News | Molecular Imaging | June 26, 2015

Navidea Reports Manocept Study Results in Rheumatoid Arthritis Radiotracer

Findings indicate higher concentration of CD206 receptor in patients with RA

Navidea, Manocept, CD206 receptor, rheumatoid arthritis

June 26, 2015 - Navidea Biopharmaceuticals announced that results from several pre-clinical Manocept studies in rheumatoid arthritis (RA) were presented at the EULAR 2015 European Congress of Rheumatology in Rome, Italy from June 10-13, 2015.  The results of studies, led by Wael Jarjour, M.D., Thomas J. Rosol, Ph.D., and Larry S. Schlesinger, M.D., of The Ohio State University Wexner Medical Center, highlighted the potential of CD206-targeting Manocept constructs to detect immune-mediated inflammation in RA ,which could be used diagnostically to monitor therapeutic efficacy or as a potential therapeutic platform.

"Diagnosing patients with RA can be challenging because the commonly used laboratory assays are negative in 20 percent of affected patients. Additionally, there are limited reliable tools to assess disease activity and guide therapy in patients with difficult clinical presentations," said  Jarjour, associate professor and director, Division of Rheumatology & Immunology, The Ohio State University Wexner Medical Center. "We believe that Manocept-targeting of macrophages shows promise in detecting immune-mediated inflammation in RA and could potentially be used diagnostically or to monitor therapeutic efficacy in patients."

The oral presentation entitled, " Manocept, a Derivative of FDA-Approved 99mTc-Tilmanocept, Exhibits Diagnostic Potential by Specifically Identifying Macrophages in Rheumatoid Arthritis: A Novel Application of an Existing Drug," ( DOI : 10.1136/annrheumdis-2015-eular. 4876) showed results from synovial fluid and tissue acquired from RA patients for comparison to normal frozen archival tissue and synovial tissue procured from patients with osteoarthritis (OA). Tissues were probed with Manocept-Cy3, DAPI nuclear stain, and anti CD206-cyanine. Mononuclear cells were isolated from RA synovial fluid and analyzed by flow cytometry. Results demonstrated that archival synovial tissue and synovial fluid obtained from patients diagnosed with RA contain a significant population of macrophages that express high levels of the CD206 receptor. It was shown that these macrophages strongly co-localize Manocept-Cy3 and CD206 receptors. The degree of macrophage infiltration in tissue from healthy or osteoarthritic patients was significantly lower than in RA tissues. 

Additionally in an in vivo animal study, arthritis was induced in mice and was followed with intravenous injection of Manocept-Cy3 and epi-fluorescent imaging. Imaging results indicated that Manocept can be detected in inflamed joints in an in vivo animal model of RA.

For more information:

Related Content

Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Icon Launches New Clinical Trial Patient Engagement Platform
Technology | Patient Engagement | May 14, 2019
Icon plc announced the release of its web-based clinical trial patient engagement platform, to provide patients with...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients
News | MRI Breast | May 09, 2019
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast...